Patent US4364934A successfully refreshed from Google Patents.
US4364934A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1979-12-04
•
Granted: 1982-12-21
•
Expires: 1999-12-04
Abstract
Abstract Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF 1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Inventors
- 👤 Patrick C. Kung
- 👤 Gideon Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 07:47
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2881; A; A61; A61P; A61P37/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/808
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
205 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells, which antibody: (a) reacts with approximately 10 percent of normal human thymocytes, but not with normal human peripheral T cells, B cells, Null cells, or bone marrow cells, (b) reacts with 8 percent of untreated thymocytes, 6 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, 12 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8001 and complement, and 5 percent of the thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014 and complement; (c) reacts with Early Thymocyte (Thy 2) Stage I and Common Thymocyte (Thy 3) Stage II T cell ALL Stages but not with Prothymocyte (Thy 1) Stage I, Common Thymocyte (Thy 4, Thy 3-4, or Thy 4-6) Stage II or Late Thymocyte (Thy 8) Stage III T cell ALL Stages; (d) reacts with HSB-2, CEM and MOLT-4 cell lines; and (e) defines a T cell antigen which appears on 30-50 percent of peripheral T cells after mitogen stimulation.
Claim 2
Dependent Claim
205 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells, which antibody: (a) reacts with approximately 10 percent of normal human thymocytes, but not with normal human peripheral T cells, B cells, Null cells, or bone marrow cells, (b) reacts with 8 percent of untreated thymocytes, 6 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, 12 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8001 and complement, and 5 percent of the thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014 and complement; (c) reacts with Early Thymocyte (Thy 2) Stage I and Common Thymocyte (Thy 3) Stage II T cell ALL Stages but not with Prothymocyte (Thy 1) Stage I, Common Thymocyte (Thy 4, Thy 3-4, or Thy 4-6) Stage II or Late Thymocyte (Thy 8) Stage III T cell ALL Stages; (d) reacts with HSB-2, CEM and MOLT-4 cell lines; and (e) defines a T cell antigen which appears on 30-50 percent of peripheral T cells after mitogen stimulation.
Claim 3
Dependent Claim
13 words
The monoclonal antibody of claim 1 which is of subclass IgG 1 .
Claim 4
Dependent Claim
34 words
The monoclonal antibody of claim 1 which is produced from a hybridoma formed by fusion of P3X63Ag8U1 myeloma cells and spleen cells from a CAF 1 mouse previously immunized with human leukemic T-ALL cells.
Claim 5
Dependent Claim
59 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells which reacts with approximately 10 percent of normal human thymocytes, but not with normal human peripheral T cells, B cells, Null cells, or bone marrow cells.
Claim 6
Dependent Claim
59 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells which reacts with approximately 10 percent of normal human thymocytes, but not with normal human peripheral T cells, B cells, Null cells, or bone marrow cells.
Claim 7
Dependent Claim
28 words
Mouse monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells.
Claim 8
Dependent Claim
28 words
Mouse monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells.
Claim 9
Dependent Claim
166 words
A monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells; and (vii) recovering the antibody from the supernatant above said clones.
Claim 10
Dependent Claim
166 words
A monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells; and (vii) recovering the antibody from the supernatant above said clones.
Claim 11
Dependent Claim
181 words
A monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, prepared by the method, which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells; (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 12
Dependent Claim
181 words
A monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, prepared by the method, which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells; (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 13
Independent Claim
53 words
A method of preparing monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, which comprises culturing the hybridoma ATCC CRL 8021 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 14
Independent Claim
53 words
A method of preparing monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, which comprises culturing the hybridoma ATCC CRL 8021 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 15
Dependent Claim
10 words
The monoclonal antibody prepared by the method of claim 8.
Claim 16
Independent Claim
55 words
A method of preparing monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8021 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 17
Independent Claim
55 words
A method of preparing monoclonal antibody which reacts with approximately 10% of normal human thymocytes but not with normal human peripheral T cells, B cells, null cells, or bone marrow cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8021 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 18
Dependent Claim
10 words
The monoclonal antibody prepared by the method of claim 10.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-12-20 | 1986-06-21 | 1986-12-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-12-20 | 1990-06-21 | 1990-12-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-12-20 | 1994-06-21 | 1994-12-21 | $7700.00 | Window Closed / Lapsed |